Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Similarities and differences between selective and nonselective BAFF blockade in murine SLE
Meera Ramanujam, … , teven Porcelli,, Anne Davidson
Meera Ramanujam, … , teven Porcelli,, Anne Davidson
Published March 1, 2006
Citation Information: J Clin Invest. 2006;116(3):724-734. https://doi.org/10.1172/JCI26385.
View: Text | PDF
Research Article Autoimmunity

Similarities and differences between selective and nonselective BAFF blockade in murine SLE

  • Text
  • PDF
Abstract

B cells have multiple roles in immune activation and inflammation separate from their capacity to produce antibodies. B cell depletion is currently under intense investigation as a therapeutic strategy for autoimmune diseases. The TNF family members B cell–activating factor of the TNF family (BAFF) and its homolog A proliferation-inducing ligand (APRIL) are B cell survival and differentiation factors and are therefore rational therapeutic targets. We compared the effects of BAFF receptor–Ig, which blocks only BAFF, with those of transmembrane activator and calcium modulator ligand interactor–Ig, which blocks both BAFF and APRIL, in a murine SLE model. Both reagents prolonged the life of NZB/W F1 mice when given either before or after disease onset. Many immunologic effects of the 2 reagents were similar, including B cell and B cell subset depletion and prevention of the progressive T cell activation and dendritic cell accumulation that occurs with age in NZB/W mice without substantial effects on the emergence of the IgG anti–double-stranded DNA response. Furthermore, both reagents inhibited the T cell–independent marginal zone B cell response to particulate antigen delivered i.v., but not the B1 B cell response to the same antigen delivered i.p. In contrast, blockade of both BAFF and APRIL, but not blockade of BAFF alone, reduced the serum levels of IgM antibodies, decreased the frequency of plasma cells in the spleen, and inhibited the IgM response to a T cell–dependent antigen. The differences between selective and nonselective BAFF blockade are relevant to the choice of a BAFF blocking agent for the treatment of autoimmune and malignant diseases.

Authors

Meera Ramanujam, Xiaobo Wang, Weiqing Huang, Zheng Liu, Lena Schiffer, Haiou Tao, Daniel Frank, Jeffrey Rice, Betty Diamond, Karl O.A. Yu, teven Porcelli,, Anne Davidson

×

Figure 2

Ad–BAFF-R–Ig prolongs survival of NZB/W F1 mice.

Options: View larger image (or click on image) Download as PowerPoint
Ad–BAFF-R–Ig prolongs survival of NZB/W F1 mice.
Kaplan-Meier plots of p...
Kaplan-Meier plots of proteinuria-free survival (A) and overall survival (B) in treated NZB/W F1 mice aged 18–20 weeks. Mice treated with Ad–BAFF-R–Ig alone or together with CTLA4Ig had prolonged survival (P < 0.0001, Ad–BAFF-R–Ig versus control; P < 0.003, Ad–BAFF-R–Ig/CTLA4Ig versus Ad-LacZ/CTLA4Ig) and prolonged proteinuria-free survival compared with untreated or irrelevant adenovirus controls (P < 0.001, Ad–BAFF-R–Ig versus untreated; P < 0.01, Ad–BAFF-R–Ig/CTLA4Ig versus Ad-LacZ/CTLA4Ig). (C) Time of appearance of high-titer IgG anti-dsDNA antibodies. In both Ad–BAFF-R–Ig– and Ad–BAFF-R–Ig/CTLA4Ig–treated groups (P < 0.0013 and P < 0.0139, respectively), there was a delay of approximately 6 weeks in the appearance of IgG anti-dsDNA antibodies compared with the relevant control.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts